2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 61, n° 5
pages 885-888 (novembre 2009)
Doi : 10.1016/j.jaad.2008.12.045
Case Reports

Intravascular large B-cell lymphoma: Remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy

Barbara Horváth, MD, PhD a, , Judit Demeter, MD, PhD, DSc c, Nóra Erős, MD a, Judit Hársing, MD, PhD a, Judit Csomor, MD, PhD b, András Matolcsy, MD, PhD, DSc b, Gyula Bottlik, MD a, Gabriella Győri, MD c, Márta Marschalkó, MD, PhD a, Sarolta Kárpáti, MD, PhD, DSc a
a Department of Dermatology, Venerology, and Dermatooncology, Semmelweis University, Budapest, Hungary 
b First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary 
c First Department of Internal Medicine, Semmelweis University, Budapest, Hungary 

Reprint requests: Barbara Horváth, MD, PhD, Department of Dermatology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.

Intravascular lymphoma is an uncommon, very aggressive extranodal non-Hodgkin lymphoma that most frequently involves the skin and central nervous system. Most cases are of B-cell origin; T-cell phenotype is extremely rare. Malignant cells proliferate within the lumens of capillaries, arterioles, venules, and small arteries; vascular occlusion is responsible for the clinical signs and symptoms. The prognosis of this high-grade B-cell lymphoma has improved since the introduction of the anti-CD20 monoclonal antibody, rituximab. We describe a case of B-cell intravascular lymphoma successfully treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone.

The full text of this article is available in PDF format.

Key words : CHOP, intravascular large B-cell lymphoma, rituximab

 Funding sources: None.
 Conflicts of interest: None declared.

© 2009  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline